

PROSONIX AND TRIMEL CONCLUDE MULTI-PRODUCT LICENCE AND CO-DEVELOPMENT AGREEMENT FOR RESPIRATORY MEDICINES

Prosonix Ltd (Oxford, UK) is delighted to announce that it has entered into a multi-product co-development and licensing agreement with a subsidiary of Trimel Biopharma Holdings (Barbados). The agreement enables the combination of Prosonix' particle engineering leadership with Trimel's award winning unit dose, single use, disposable dry powder inhaler technology.

Prosonix' proprietary particle engineering technologies deliver unique, crystalline, excipient free, highly performing, stable drug particles that offer significant and distinct and quantifiable advantages over current industry practice, eliminating variability in drug product and formulation performance with respect to delivered dose, dose content uniformity, dose-to-dose variation, and shelf life.

Trimel's **TriVair™** proprietary device technology is focused on the delivery of pharmaceutical compounds through pulmonary inhalation and nasal dispersion systems that utilize unique patent protected dosing technologies. These technologies are applicable to numerous pharmaceutical compounds and are suitable for multiple indications.

*Commenting on the deal, **David Hipkiss** Prosonix CEO said*

"We are delighted to be partnered with Trimel in this exciting arrangement. Prosonix is focused on "Making Better Medicines™" and the combination of designed for purpose engineered drug particles with Trimel's best-in-class novel dry powder inhalers delivering optimal inhalation performance validates our long held strategic Vision."

For more information contact:

David Hipkiss
CEO
Prosonix Ltd
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA, UK

Tel + 44 (0) 1865 784 250
Web www.prosonix.co.uk